TransThera Sciences (02617.HK) saw its stock soar by 8.53% during intraday trading on Friday, as part of a broader surge in Hong Kong's biotech sector. The significant uptick in TransThera's share price reflects the strong momentum currently driving biotech stocks in the region.

The rally in biotech stocks was widespread, with several companies in the sector posting impressive gains. Cutia Therapeutics led the pack with a 14% increase, followed by Antengene with a 13% rise. TransThera Sciences and HBM Holdings both saw their stocks climb by approximately 9%, while other notable performers included RemeGen with an 8% increase, and CARsgen Therapeutics, which advanced by 7%.

This surge in biotech stocks suggests a renewed investor interest in the sector, possibly driven by positive industry developments or broader market trends favoring growth and innovation-focused companies. TransThera Sciences' strong performance, in particular, may indicate positive sentiment surrounding the company's research pipeline or market position within the competitive biotech landscape.